Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 62

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 62
---
 shareholders, directors and officers have agreed
(and their permitted transferees will agree), pursuant to the terms of a letter agreement, to vote any shares held by them in favor of
the initial Business Combination.

6

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

The
underwriters have agreed to waive their rights to their deferred underwriting commissions (see Note 6) held in the Trust Account
in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will
be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the
event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than
the Initial Public Offering price per Unit ($10.00).

The
Company will have until 15 months from the closing of the Initial Public Offering (April 29, 2026) to complete a Business Combination.
However, if the Company is unable to complete the initial Business Combination within 15 months from the closing the Initial Public
Offering, the time period to complete an initial Business Combination can be extended without shareholder approval up to two times, each
by an additional three months (for a total of up to 21 months to complete an initial Business Combination) (the “Combination
Period”), subject to the Sponsor depositing into the Trust Account $0.10 per public share outstanding in connection with each
such extension. If the Company has not completed a Business Combination within the Combination Period, the Company will (i) cease
all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days
thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account, including interest earned on the funds held in the Trust Account (net of funds withdrawn to pay taxes, if any, and up to $100,000
of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will completely
extinguish public shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any),
and (iii)